Lilly Builds Neuroscience into a New Long-Term Growth Driver

Eli Lilly's neuroscience revenue rose approximately 32% year over year to $811 million in the first half of 2026, though the segment remains only about 2% of total sales versus cardiometabolic products' roughly 80% contribution. Lilly is expanding its neuroscience pipeline through internal development and acquisitions, including the planned purchase of AtaiBeckley and the addition of Centessa's cleminorexton, to diversify beyond GLP-1 therapies. Consensus EPS estimates increased to $35.93 for 2026 from $35.56 and to $45.93 for 2027 from $44.58 over 60 days, although the stock trades at a 26.85x forward P/E and has gained 6.9% year to date, trailing the industry's 14.5% rise.

Analysis

Neuroscience is strategically valuable to LLY chiefly as a duration asset, not a near-term EPS driver: even material outperformance in Alzheimer’s or sleep medicine will not offset a cardiometabolic disappointment over the next 1-3 quarters. The market is likely to value the franchise through de-risking milestones—phase III readouts, payer coverage expansion, and evidence of infusion-center capacity—rather than current sales. This means pipeline wins can support LLY’s terminal multiple, but the stock remains more exposed to tirzepatide volume, net-price, and supply assumptions than to neuroscience execution.

In Alzheimer’s, commercial adoption is constrained less by physician awareness than by diagnostic workflows, MRI monitoring requirements, and ARIA-related risk management. Those frictions favor scaled incumbents with provider infrastructure and field reimbursement capabilities, but they also cap the near-term market expansion implied by optimistic peak-sales assumptions. BIIB is the cleaner relative read-through: incremental category adoption improves Leqembi utilization and can drive disproportionate estimate revisions from a lower earnings base, whereas LLY’s Alzheimer’s upside is diluted within a much larger enterprise.

ATAI is a special-situations watch rather than a standalone fundamental long until consideration, closing conditions, and post-acquisition development funding are verified. Rapid-acting depression programs carry unusually binary regulatory and durability risk; a successful trial could create strategic scarcity for CNS assets, while an efficacy or safety miss would have negligible financial consequence for LLY but substantial downside for ATAI. The contrarian view is that diversification M&A may be more defensive than accretive: if GLP-1 cash flows remain strong, investors may penalize LLY for paying premium prices for early-stage optionality rather than reward portfolio breadth.

Key Decisions for Investors

• Maintain LLY as a core long only if cardiometabolic estimate momentum remains intact; use neuroscience milestones as upside optionality rather than the underwriting thesis. Reassess if 2027 EPS consensus stops rising or management reduces tirzepatide volume/net-price guidance, either of which would challenge a premium multiple over the next 1-3 months.
• Consider a 6-12 month long BIIB / short LLY relative-value position for investors seeking Alzheimer’s-category exposure with less GLP-1 concentration risk. BIIB offers greater earnings and multiple sensitivity to category uptake; exit if Leqembi adoption fails to translate into sequential revenue acceleration or if LLY demonstrates clearly superior payer/access traction.
• Do not initiate ATAI on the acquisition narrative without confirmed transaction terms and closing timetable. Set an event-driven alert for definitive merger documentation, financing requirements, and BPL-003 pivotal-trial design; only evaluate a deal-spread long if annualized spread return compensates for clinical and closing risk.
• Avoid shorting AMGN, ABBV, PFE, TEVA, or NVS solely on migraine competition: CGRP share shifts are unlikely to be material enough to alter group earnings. The more actionable catalyst is any payer formulary change or migraine-prescription trend that signals whether branded CGRP competition is becoming price-destructive over the next 6-18 months.